NewAmsterdam Pharma: Obicetrapib Is More Than Another LDL-Lowering Pill
We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to best-in-class tools. Invest.","telephone":"+1-347-509-6837","url":"https://seekingalpha.com"},"datePublished":"2026-07-26T03:58:33.000Z","dateModified":"2026-07-26T04:01:16.000Z","description":"NewAmsterdam Pharma (NAMS) outlook: obicetrapib could cut cardiovascular risk beyond LDL-C. Dragos Condrea/iStock via Getty Images I think NewAmsterdam Pharma (NAMS) is in a promising position because I believe obicetrapib is currently being viewed as just another cholesterol-lowering drug to lower LDL-C.
- ▪We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to best-in-class tools.
- ▪Invest.","telephone":"+1-347-509-6837","url":"https://seekingalpha.com"},"datePublished":"2026-07-26T03:58:33.000Z","dateModified":"2026-07-26T04:01:16.000Z","description":"NewAmsterdam Pharma (NAMS) outlook: obicetrapib could cut cardiovas
- ▪Dragos Condrea/iStock via Getty Images I think NewAmsterdam Pharma (NAMS) is in a promising position because I believe obicetrapib is currently being viewed as just another cholesterol-lowering drug to lower LDL-C.
Seeking Alpha files mainly under finance. We currently carry 6,451 of its stories.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4925643-newamsterdam-pharma-obicetrapib-is-more-than-another-ldl-lowering-pill"},"author":{"@type":"Person","name":"Equity…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
